ReposiTrak, Inc. Q4 FY2024 earnings call

• Milestone year: Increased recurring revenue, delivered solid margins, grew net income and EPS. Added cash to balance sheet (highest in company history). Returned over $5.6 million to shareholders. Invested in sales, marketing, cybersecurity, development platform, and implementation resources.
• Entered fiscal 2025 with tailwinds and competitive position. Eliminated $1.4 million of high touch low opportunity revenue. Traceability revenue represented 6% of total revenue in fiscal 2024.
• Plan to double annual recurring revenue run rate in traceability over 3 years with 80%+ margins. Fiscal 2024 total revenue up 7%, recurring revenue 99% of total. Operating expenses up 10% due to RTN, cybersecurity, sales/marketing investments.
• Repurchased 177,000 common shares, redeemed 220,000 preferred shares, increased quarterly common stock dividend, fully paid off line of credit, had over $25 million cash. Traceability enrollment is a complex multistep process but accelerating. Compliance and supply chain solutions also growing.

Fourth quarter fiscal 2024: Total revenue was $5.2 million, up 8% from $4.8 million. Recurring revenue was 100% of total revenue. Operating expenses were $3.9 million, up 6% from $3.6 million. GAAP net income was $1.6 million, up 15% from $1.4 million. GAAP net income to common shareholders was $1.5 million, up 18% from $1.2 million. EPS was $0.08 per share compared to $0.07 per share last year. Full fiscal year 2024: Total revenue was up 7%, with recurring revenue 99% of total revenue. Operating expenses increased 10% due to investments in the ReposiTrak Traceability Network, cybersecurity, and sales/marketing. GAAP net income was $5.9 million, up 7% from $5.6 million. GAAP net income to common shareholders was $5.4 million, up 8% from $5 million. EPS was $0.30 basic and $0.29 diluted compared to $0.27 per share last year. Traceability solution contributed 6% of total revenue in fiscal 2024, approximately $1.2 million.

• Expect traceability contribution to increase sequentially in fiscal 2025 and accelerate. Current FDA deadline is January 2026, but market forces are accelerating demand. Board approved 10% increase in quarterly common stock cash dividend starting December 31, 2024. Plan to redeem all preferred shares in remaining two years. Intend to return at least half annual cash from operations to shareholders via dividend, buybacks, etc.

• Difficulty forecasting enrollment trajectory due to complex FDA mandate process. Uncertainty around supplier adoption and data collection complexities. Risk of not maintaining flawless execution which could jeopardize customer delivery. Potential impact of market forces and competition on growth.

Q: Have you finished adjusting your customer portfolio to remove high touch low margin ones or is that a permanent effort?

A: Randy says from current position, yes, but not 100% certain it's permanent as traceability may bring new layers.

Q: Thoughts on adjacent regulated markets like restaurants, healthcare?

A: Randy says they look at market size, profitability, and have new follow-on products coming, plan to push into other verticals.

Q: Updates on international efforts?

A: Randy says focused on US execution with thousands of suppliers onboarded, but US platform likely dominant outside US, approach via ventures.

Q: Consideration of one-time dividend?

A: John says not off the table, but prefers quarterly dividend for line of sight.

Q: AI efforts and impact on top/bottom line?

A: Randy says AI used to help employees make better decisions, reduce admin, and has potential to double company size without additional people.

Q: Update on cost to run business?

A: John says it takes ~$12 million to run, may fluctuate with investments but expects to stabilize.

Q: Thoughts on M&A?

A: Randy says focused on execution with 4,000 suppliers onboarded, risk of taking eye off ball, so currently laser focused on execution.